151 related articles for article (PubMed ID: 8750649)
1. Prostate-specific antigen (PSA) and cancer-associated serum antigen (CASA) in distinguishing benign and malignant prostate disease.
Devine PL; Walsh MD; McGuckin MA; Quin RJ; Hohn BG; Clague A; Samaratunga H
Int J Biol Markers; 1995; 10(4):221-5. PubMed ID: 8750649
[TBL] [Abstract][Full Text] [Related]
2. Tissue polypeptide-specific antigen: a discriminative parameter between prostate cancer and benign prostatic hypertrophy.
Marrink J; Oosterom R; Bonfrer HM; Schröder FH; Mensink HJ
Eur J Cancer; 1993; 29A(4):570-1. PubMed ID: 7679580
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen (protein and mRNA) analysis in the differential diagnosis and staging of prostate cancer.
Castaldo G; Cecere G; di Fusco V; Prezioso D; d'Armiento M; Salvatore F
Clin Chim Acta; 1997 Sep; 265(1):65-76. PubMed ID: 9352130
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer.
Zidan HE; Abdul-Maksoud RS; Elsayed WSH; Desoky EAM
IUBMB Life; 2018 May; 70(5):437-444. PubMed ID: 29522280
[TBL] [Abstract][Full Text] [Related]
5. Measurement of prostate specific antigen and gamma-seminoprotein ratio: a new means of distinguishing benign prostatic hyperplasia and prostate cancer.
Demura T; Watarai Y; Togashi M; Hirano T; Ohashi N; Koyanagi T
J Urol; 1993 Nov; 150(5 Pt 2):1740-5. PubMed ID: 7692111
[TBL] [Abstract][Full Text] [Related]
6. Serum-to-urinary prostate-specific antigen ratio: a potential means of distinguishing benign prostatic hyperplasia from prostate cancer.
Irani J; Millet C; Levillain P; Doré B; Begon F; Aubert J
Eur Urol; 1996; 29(4):407-12. PubMed ID: 8791046
[TBL] [Abstract][Full Text] [Related]
7. Tissue polypeptide-specific antigen (TPS) immunoassay in the diagnosis and clinical staging of prostatic carcinoma. Comparison with prostate-specific antigen (PSA).
Ceriani L; Giovanella L; Salvadore M; Bono AV; Roncari G
Int J Biol Markers; 1997; 12(1):27-34. PubMed ID: 9176715
[TBL] [Abstract][Full Text] [Related]
8. Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen.
Steuber T; Nurmikko P; Haese A; Pettersson K; Graefen M; Hammerer P; Huland H; Lilja H
J Urol; 2002 Nov; 168(5):1917-22. PubMed ID: 12394676
[TBL] [Abstract][Full Text] [Related]
9. [Improved discrimination between prostatic carcinoma and benign prostatic hyperplasia by determination of free prostate-specific antigen percentage].
Wolff JM; Borchers H; Boeckmann W; Habib FK; Jakse G
Urologe A; 1997 May; 36(3):255-8. PubMed ID: 9265347
[TBL] [Abstract][Full Text] [Related]
10. Correlation of prostate-specific antigen and prostate-specific antigen density with outcome of prostate biopsy.
Bare R; Hart L; McCullough DL
Urology; 1994 Feb; 43(2):191-6. PubMed ID: 7509526
[TBL] [Abstract][Full Text] [Related]
11. Detection of prostate carcinoma using prostate specific antigen, its density, and the density of the transition zone in Japanese men with intermediate serum prostate specific antigen concentrations.
Gohji K; Nomi M; Egawa S; Morisue K; Takenaka A; Okamoto M; Ohori M; Fujii A
Cancer; 1997 May; 79(10):1969-76. PubMed ID: 9149025
[TBL] [Abstract][Full Text] [Related]
12. Prostate tissue and serum markers.
Mazzucchelli R; Colanzi P; Pomante R; Muzzonigro G; Montironi R
Adv Clin Path; 2000 Jul; 4(3):111-20. PubMed ID: 11080790
[TBL] [Abstract][Full Text] [Related]
13. A novel multiplex assay combining autoantibodies plus PSA has potential implications for classification of prostate cancer from non-malignant cases.
Xie C; Kim HJ; Haw JG; Kalbasi A; Gardner BK; Li G; Rao J; Chia D; Liong M; Punzalan RR; Marks LS; Pantuck AJ; de la Taille A; Wang G; Mukouyama H; Zeng G
J Transl Med; 2011 Apr; 9():43. PubMed ID: 21504557
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic accuracy of percent free prostate-specific antigen in prostatic pathology and its usefulness in monitoring prostatic cancer patients.
Minardi D; Galosi AB; Recchioni A; Giammarco L; Polito M; Muzzonigro G
Urol Int; 2001; 67(4):272-82. PubMed ID: 11741128
[TBL] [Abstract][Full Text] [Related]
15. Lymphocyte-to-monocyte ratio is a valuable marker to predict prostate cancer in patients with prostate specific antigen between 4 and 10 ng/dl.
Caglayan V; Onen E; Avci S; Sambel M; Kilic M; Oner S; Aydos MM; Yıldız HE
Arch Ital Urol Androl; 2019 Jan; 90(4):270-275. PubMed ID: 30655640
[TBL] [Abstract][Full Text] [Related]
16. Optimum PSA reflex-range.
Benecchi L
Arch Ital Urol Androl; 2006 Jun; 78(2):44-8. PubMed ID: 16929601
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen (PSA) in the management of 500 prostatic patients.
Guillet J; Role C; Duc AT; François H
Am J Clin Oncol; 1988; 11 Suppl 2():S61-2. PubMed ID: 2468274
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen density: correlation with histological diagnosis of prostate cancer, benign prostatic hyperplasia and prostatitis.
van Iersel MP; Witjes WP; de la Rosette JJ; Oosterhof GO
Br J Urol; 1995 Jul; 76(1):47-53. PubMed ID: 7544204
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia.
Bogdanowicz JF; Bentvelsen FM; Oosterom R; Schroeder FH
Scand J Urol Nephrol Suppl; 1991; 138():97-103. PubMed ID: 1723815
[TBL] [Abstract][Full Text] [Related]
20. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer.
Benson MC; Whang IS; Pantuck A; Ring K; Kaplan SA; Olsson CA; Cooner WH
J Urol; 1992 Mar; 147(3 Pt 2):815-6. PubMed ID: 1371554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
